South Rampart Pharma receives $1.9M NIH STTR Fast-Track Grant
PAIN RELIEF INNOVATION
South Rampart Pharma is a clinical-stage life science company that aims to advance the safe treatment of pain by developing new small-molecule solutions that can overcome many risks associated with current pain medicines. The Company’s pipeline of novel compounds have effectively reduced both pain and fever in preclinical studies without the liver and kidney toxicity of current non-opioid analgesics. The Company’s lead program SRP-3D (Diethylamide [DA]), is currently in a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics with data expected in the second half of 2022.